Tag: argenx

May 28, 2019

8 Small Biotech ETFs

Want to invest in small biotech ETFs? Here we profile eight that life science investors may want to look into.
December 19, 2018

Biotech Outlook 2019: Will the Pressure Continue?

With 2018 coming to an end, what's the biotech outlook? Next year will bring new investing opportunities for those in...
October 3, 2018

VIDEO — Life Science Update September 2018

With September officially behind us, the Investing News Network is taking a look back at some of the biggest news...
September 17, 2018

Argenx Releases Positive Trial Results

On Monday, Argenx released positive clinical data from a proof-of-concept trial for its rare disease drug, efgartigimoid (ARGX-113).
September 17, 2018

argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

argenx (Nasdaq:ARGX) announced positive topline results from its Phase 2 proof-of-concept clinical trial of efgartigimod (ARGX-113) in adult primary immune...
June 6, 2018

argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment...
May 9, 2018

argenx reports first quarter 2018 financial results and provides business update

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment...